Aptamer Group secures new contracts worth up to £471,000

Aptamer Group

Aptamer Group plc (LON:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has provided an update on contracts signed since its financial year ended 30 June 2024.

Aptamer has secured new contracts worth up to £471,000 continuing the positive commercial traction achieved during the last quarter of the previous financial year. These contracts include multiple agreements, including two from top 20 and one from a top 5 global pharmaceutical companies, totalling up to £340,000. These projects are aimed at developing Optimers as critical reagents to support active clinical development programmes and facilitate the analysis of novel therapeutics.

A significant proportion of these deals involve repeat customers who are advancing Aptamer’s binders within their internal pipelines, with some signalling intent for long-term licensing revenues. This ongoing traction highlights Aptamer’s role in supporting key industry players and reinforces our position as a key player in the market.

These new contracts illustrate Aptamer’s increasing commercial traction and the Group’s ability to secure repeat business from top pharmaceutical companies. Aptamer now has booked revenue contracts of up to c. £1.2m to recognise throughout FY25 (Jun 25 year-end) and an increased sales pipeline from £2.1m in July 2024 to £4.0m as of today.

Dr Arron Tolley, Chief Executive Officer of Aptamer Group said: “Following the fundraise in August 2024, I am pleased to report that the sustained focus of our commercial team continues to bear fruit. We are advancing steadily towards our revenue and potential licensing goals for FY 25 with the best part of 7 months left in the financial year. Revenue generation and increased income from licensing form a pivotal component of the Group’s strategy to deliver shareholder value and I look forward to updating you on future contracts and key project updates.”  

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

    Aptamer secures repeat contracts and new licensing deals

    Aptamer Group plc announces promising new data on its Optimer therapeutic delivery platform for liver fibrosis, showcasing broad therapeutic potential across various diseases.

    Aptamer adapts Alzheimer’s test to ELISA and signs royalty deal

    Aptamer Group announces a breakthrough in Alzheimer's diagnostics with a new ELISA test utilising saliva samples, enhancing accessibility and rapid detection.

    Aptamer licences Optimer binders for swine vaccines

    Aptamer Group plc has secured a significant global licensing deal with the University of Glasgow, advancing synthetic binders for vaccines in swine health.

    Aptamer to present Optimer® liver targeting data at 2025 ASGCT

    Aptamer Group plc is set to unveil groundbreaking data on its Optimer® delivery vehicle for fibrotic liver disease at the 2025 ASGCT Annual Meeting.

    Aptamer Group publishes new Corporate Presentation and Investor Factsheet

    Aptamer Group plc has released a new corporate presentation and investor factsheet, showcasing its strategic growth, operational progress, and financial performance in the life science industry.

    Aptamer Group reports revenue growth and solid cash position in H1 2025

    Aptamer Group plc reports impressive interim results for H1 2025, highlighting revenue growth and strategic advancements in life sciences innovation.

      Search

      Search